Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003

Documenti analoghi

• Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of <it>Streptococcus pneumoniae </it>by clinical laboratories in the United States during 2002 and 2003
  di: Thornsberry Clyde, et al.
  Pubblicazione: (2004-01-01)
• In Vitro Activities of Broad-Spectrum Cephalosporins against Nonmeningeal Isolates of Streptococcus pneumoniae: MIC Interpretation Using NCCLS M100-S12 Recommendations
  di: Sahm, Daniel F., et al.
  Pubblicazione: (2002)
• Reinterpretation of Susceptibility Data Using Current NCCLS Breakpoint Criteria
  di: Jones, Mark E., et al.
  Pubblicazione: (2003)
• In Vitro Susceptibilities of Gram-Negative Bacteria Isolated from Hospitalized Patients in Four European Countries, Canada, and the United States in 2000-2001 to Expanded-Spectrum Cephalosporins and Comparator Antimicrobials: Implications for Therapy
  di: Wenzel, Richard P., et al.
  Pubblicazione: (2003)
• Impact of Modified Nonmeningeal Streptococcus pneumoniae Interpretive Criteria (NCCLS M100-S12) on the Susceptibility Patterns of Five Parenteral Cephalosporins: Report from the SENTRY Antimicrobial Surveillance Program (1997 to 2001)
  di: Jones, Ronald N., et al.
  Pubblicazione: (2002)